Get Flat 15% Discount on ED Drugs for orders value $70 or more
  • Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter

      Lupin gets US FDA nod for anti-depressant


      MUMBAI: Drug maker Lupin has received US Food and Drug Association (FDA) approval for anti-depressant, it said on Wednesday. Lupin can now make Imipramine hydrochloride tablets of 10 mg, 25 mg and 50 mg strengths, as per the abbreviated new drug application (ANDA) approval, the company said. Shipments for the product are already on way, Nilesh Gupta, group president and executive director, told ET.

      The company estimates the market size for the product at $21 million (approximately Rs 95 crore) in the US. Lupin had filed 105 ANDAs as on December 31, 2009, and has received approval for 36.

      The approval marks the company’s fifth drug approval since January, when the FDA cleared its objections to Lupin’s Mandideep facility. While the curb on the Mandideep facility didn’t bar most of the product approvals Lupin has sought, there could have been a sentimental impact at the regulators end, analysts said.

      Indian pharmaceutical companies have been under heightened scrutiny lately, even as the Obama administration seeks to liberalise the use of generic drugs and lower costs of the country’s social security programme. Others like Ranbaxy and Sun Pharmaceutical’s US unit Caraco Pharmaceutical Laboratories continue to face warnings against manufacturing processes.

      March 22, 2010


      Share this Article!

    Back to top^